CDK12 and cancer: On the other hand, our results suggest that CDK12 loss of heterozygosity engenders the incipient cancer cells with augmented oncogenic signaling that drive key hallmarks of cancer, which in the case of NF-kB signaling include sustained proliferative signaling, avoidance of programmed cell death, tumor-promoting inflammation and therapy resistance (86).